| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 7, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 7, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2022 | $10.00 | Buy | Dawson James |
8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The Series F warrants have an exercise price of $1.75 per share a
ACTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient solutions for critical care, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrant in lieu thereof) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The Series F warrants will have an exercise price of $
ACTON, Mass. and YAMANASHI, Japan, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay"), a medical diagnostics company focused on developing rapid near-patient testing solutions for critical care, today announced that it has entered into an Agreement to Amend the Master Service Agreement and the Master Supply Agreement with SanyoSeiko Co., Ltd. ("SanyoSeiko"), a Japan-based contract manufacturer specializing in medical devices and precision engineering. The amended agreement was entered into in connection with Bluejay expanding SanyoSeiko's role in helping to commercialize Bluejay's Symphony platform, a near-patient testing system designed to provide rapid
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.
ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa
SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)
SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)